Results 21 to 30 of about 8,426 (140)

Abundant intracellular IgG in enterocytes and endoderm lacking FcRn.

PLoS ONE, 2013
FcRn, a non-classical MHCI molecule, transports IgG from mother to young and regulates the rate of IgG degradation throughout life. Brambell proposed a mechanism that unified these two functions, saying that IgG was pinocytosed nonspecifically by the ...
Sudhasri Mohanty, Jonghan Kim, Latha P Ganesan, Gary S Phillips, John M Robinson, Clark L Anderson   +5 more
doaj   +1 more source

Fully human monoclonal antibody inhibitors of the neonatal Fc receptor (FcRn) reduce circulating IgG in nonhuman primates

Frontiers in Immunology, 2015
The therapeutic management of antibody mediated autoimmune disease typically involves immunosuppressant and immunomodulatory strategies. However, perturbing the fundamental role of the neonatal Fc receptor (FcRn) in salvaging IgG from lysosomal ...
Andrew E Nixon, Jie eChen, Daniel J Sexton, Arumugam eMuruganandam, Alan J Bitonti, Jennifer eDumont, Malini eViswanathan, Diana eMartik, Dina eWassaf, Adam eMezo, Clive R Wood, Joseph C Biedenkapp, Christopher eTenHoor   +12 more
doaj   +1 more source

Lack of FcRn Impairs Natural Killer Cell Development and Functions in the Tumor Microenvironment

Frontiers in Immunology, 2018
The neonatal Fc receptor (FcRn) is responsible for the recycling and transcytosis of IgG and albumin. FcRn level was found altered in cancer tissues and implicated in tumor immunosurveillance and neoplastic cell growth.
Diana Cadena Castaneda, Diana Cadena Castaneda, Christine Dhommée, Christine Dhommée, Thomas Baranek, Thomas Baranek, Emilie Dalloneau, Emilie Dalloneau, Laurie Lajoie, Laurie Lajoie, Alexandre Valayer, Alexandre Valayer, Christophe Arnoult, Christophe Arnoult, Marie-Véronique Demattéi, Marie-Véronique Demattéi, Delphine Fouquenet, Delphine Fouquenet, Christelle Parent, Christelle Parent, Nathalie Heuzé-Vourc'h, Nathalie Heuzé-Vourc'h, Valérie Gouilleux-Gruart, Valérie Gouilleux-Gruart   +23 more
doaj   +1 more source

Binding to the neonatal Fc receptor enhances the pathogenicity of anti-desmoglein-3 antibodies in keratinocytes

Frontiers in Immunology
The neonatal Fc receptor (FcRn) is important for numerous cellular processes that involve antibody recycling and trafficking. A major function of FcRn is IgG recycling and half-life prolongation, and FcRn blockade results in a reduction of autoantibodies
Anna Zakrzewicz, Katrien Vanderheyden, Yad Galaly, Simon Feldhoff, Magdalena Sips, Maximilian Brinkhaus, Ritva Tikkanen   +6 more
doaj   +1 more source

Human IgE does not bind to human FcRn

Scientific Reports, 2022
The neonatal Fc receptor (FcRn) is known to mediate placental transfer of IgG from mother to unborn. IgE is widely known for triggering immune responses to environmental antigens.
Maximilian Brinkhaus, Elvera J. van der Kooi, Arthur E. H. Bentlage, Pleuni Ooijevaar-de Heer, Ninotska I. L. Derksen, Theo Rispens, Gestur Vidarsson   +6 more
doaj   +1 more source

Dual Blockade of LILRB1 and LILRB2 Enhances Antiviral Immune Responses in SIV Infection

Advanced Science, EarlyView.
Dual LILRB1/B2 blockade with mac20G10 reshapes myeloid activation during acute SIV infection by targeting LILRB1 and LILRB2 on myeloid cells. This treatment enhances CD80 expression on selected myeloid subsets and increases plasma IFN‐λ, IL‐8, and IL‐1RA.
Florian Meurisse, Sixtine Coindre, Anne Wijkhuisen, Romain Marlin, Laure Fournier Le Ray, Juliette Pons, Melyssa Yaugel‐Novoa, Véronique Avettand‐Fenoel, Laurent Abi‐Rached, Anne‐Sophie Gallouet, Francis Relouzat, Mael Gourves, Asier Saez‐Cirion, Hisashi Arase, Gerard Zurawski, Sandra Zurawski, Nathalie Dereuddre‐Bosquet, Roger Le Grand, Stéphanie Simon, Olivier Lambotte, Benoit Favier   +20 more
wiley   +1 more source

The Dual Targeting of FcRn and FcγRs via Monomeric Fc Fragments Results in Strong Inhibition of IgG-Dependent Autoimmune Pathologies

Frontiers in Immunology, 2021
Novel molecules that directly target the neonatal Fc receptor (FcRn) and/or Fc gamma receptors (FcγRs) are emerging as promising treatments for immunoglobulin G (IgG)-dependent autoimmune pathologies.
Céline Monnet, Emilie Jacque, Christophe de Romeuf, Alexandre Fontayne, Toufik Abache, Nathalie Fournier, Gilles Dupont, Delphine Derache, Anais Engrand, Aurélie Bauduin, Aurélie Terrier, Alexander Seifert, Cécile Beghin, Alain Longue, Nicholas Masiello, Laetitia Danino, Michel Nogre, Anais Raia, Frederic Dhainaut, Louis Fauconnier, Dieudonnée Togbe, Carmen Reitinger, Falk Nimmerjahn, Wil Stevens, Sami Chtourou, Philippe Mondon   +25 more
doaj   +1 more source

Toward Personalized Theranostics: A Modular PET Platform for Antibody‐Based Imaging and Therapy

Advanced Science, EarlyView.
This modular, site‐specific antibody platform enables customizable conjugates for PET imaging and therapy. Interchangeable payloads – including radiometals, cytotoxics, and fluorophores – support adaptable, multimodal applications with limited off‐target effects. In vivo, the DFO/DOTAGA bischelate immunoconjugate provided clear tumor delineation in PET/
Delphine Vivier, Megane Grah Kple, Julen Ariztia, Marion Leroux, Mathieu Moreau, Michael Claron, Maxime Cheveau, Adam Laouafa, Agnieszka Kownacka, Camille Petitot, John Simonet, Alexandre M. M. Dias, Sophie Poty, Charles Truillet, Bertrand Collin, Alexandra Oudot, Franck Denat   +16 more
wiley   +1 more source

Targeted Lysosomal Degradation of Extracellular and Membrane Proteins: From Receptor Hijacking to Programmable Endolysosomal Routing

Advanced Science, EarlyView.
Targeted chimeric degraders engage extracellular or membrane proteins and endocytosable cell‐surface receptors, forming ternary complexes that induce receptor‐mediated internalization. Following endocytosis, post‐endocytic sorting—not internalization alone—determines target fate.
Ke Liu, Xiyan Wang, Xiaozhen Liu, Chaoqi He, Da Qian, Xuli Meng, Liquan Zhu   +6 more
wiley   +1 more source

Selection of IgG variants with increased FcRn binding using random and directed mutagenesis: impact on effector functions

Frontiers in Immunology, 2015
Despite the reasonably long half-life of IgGs, market pressure for higher patient convenience while conserving efficacy continues to drive IgG half-life improvement.
Céline eMonnet, Sylvie eJorieux, Nathalie eFournier, Rémi eUrbain, Khalil eBouayadi, Christophe eDe Romeuf, Christian K Behrens, Alexandre eFontayne, Philippe eMondon   +8 more
doaj   +1 more source